SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000875320-22-000019
Filing Date
2022-07-05
Accepted
2022-07-05 16:08:34
Documents
12
Period of Report
2022-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K vrtx-20220701.htm   iXBRL 8-K 35248
  Complete submission text file 0000875320-22-000019.txt   172876

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrtx-20220701.xsd EX-101.SCH 1993
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrtx-20220701_lab.xml EX-101.LAB 24229
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrtx-20220701_pre.xml EX-101.PRE 12685
6 EXTRACTED XBRL INSTANCE DOCUMENT vrtx-20220701_htm.xml XML 10658
Mailing Address 50 NORTHERN AVENUE BOSTON MA 02210
Business Address 50 NORTHERN AVENUE BOSTON MA 02210 6173416393
VERTEX PHARMACEUTICALS INC / MA (Filer) CIK: 0000875320 (see all company filings)

IRS No.: 043039129 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19319 | Film No.: 221064916
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences